Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir

Mark A WainbergMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, CanadaAbstract: A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non-nucleoside reverse transcriptase inhibitor. This revi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Wainberg MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/e81b2cf6700847678fb5c4b93433187a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e81b2cf6700847678fb5c4b93433187a
record_format	dspace
spelling	oai:doaj.org-article:e81b2cf6700847678fb5c4b93433187a2021-12-02T01:31:56ZCombination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir1179-1373https://doaj.org/article/e81b2cf6700847678fb5c4b93433187a2013-02-01T00:00:00Zhttp://www.dovepress.com/combination-therapies-effectiveness-and-adherence-in-patients-with-hiv-a12146https://doaj.org/toc/1179-1373Mark A WainbergMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, CanadaAbstract: A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non-nucleoside reverse transcriptase inhibitor. This review focuses on the clinical utility of rilpivirine in terms of efficacy and virologic suppression, drug resistance, drug-drug interactions, and safety. The rilpivirine-tenofovir-emtricitabine combination is a safe and effective regimen for use in most patients who are ready to start first-line anti-human immunodeficiency virus therapy. Although drug resistance can be a problem in patients who initiate therapy on rilpivirine-based regimens with viral loads &gt; 100,000 copies of viral RNA/mL, this problem can be alleviated by first starting therapy with efavirenz-tenofovir-emtricitabine for several months to suppress viral load to &lt;50 copies/mL before switching to rilpivirine-based therapy. E138K is the most important mutation associated with resistance against rilpivirine and its development must be avoided whenever possible, because this mutation confers broad cross-resistance against all approved members of the non-nucleoside reverse transcriptase inhibitor family of drugs.Keywords: non-nucleoside reverse transcriptase inhibitors, rilpivirine, human immunodeficiency virus, treatment, resistanceWainberg MADove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2013, Iss default, Pp 41-49 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Wainberg MA Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
description	Mark A WainbergMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, CanadaAbstract: A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non-nucleoside reverse transcriptase inhibitor. This review focuses on the clinical utility of rilpivirine in terms of efficacy and virologic suppression, drug resistance, drug-drug interactions, and safety. The rilpivirine-tenofovir-emtricitabine combination is a safe and effective regimen for use in most patients who are ready to start first-line anti-human immunodeficiency virus therapy. Although drug resistance can be a problem in patients who initiate therapy on rilpivirine-based regimens with viral loads &gt; 100,000 copies of viral RNA/mL, this problem can be alleviated by first starting therapy with efavirenz-tenofovir-emtricitabine for several months to suppress viral load to &lt;50 copies/mL before switching to rilpivirine-based therapy. E138K is the most important mutation associated with resistance against rilpivirine and its development must be avoided whenever possible, because this mutation confers broad cross-resistance against all approved members of the non-nucleoside reverse transcriptase inhibitor family of drugs.Keywords: non-nucleoside reverse transcriptase inhibitors, rilpivirine, human immunodeficiency virus, treatment, resistance
format	article
author	Wainberg MA
author_facet	Wainberg MA
author_sort	Wainberg MA
title	Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
title_short	Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
title_full	Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
title_fullStr	Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
title_full_unstemmed	Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
title_sort	combination therapies, effectiveness, and adherence in patients with hiv infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/e81b2cf6700847678fb5c4b93433187a
work_keys_str_mv	AT wainbergma combinationtherapieseffectivenessandadherenceinpatientswithhivinfectionclinicalutilityofasingletabletofemtricitabinerilpivirineandtenofovir
_version_	1718403047384678400

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir

Ejemplares similares